1. MAPK/ERK Pathway
  2. MNK

MNK

Mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2) phosphorylate the oncogene eIF4E on serine 209. This phosphorylation has been reported to be required for its oncogenic activity. Eukaryotic initiation factor 4E (eIF4E) is a key component of the translational machinery and an important modulator of cell growth and proliferation. The activity of eIF4E is thought to be regulated by interaction with inhibitory binding proteins (4E-BPs) and phosphorylation by mitogen-activated protein (MAP) kinase-interacting kinase (MNK) on Ser209 in response to mitogens and cellular stress.

MNK Related Products (3):

Cat. No. Product Name Effect Purity
  • HY-100022
    eFT508 Inhibitor 99.49%
    eFT508 is a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, with IC50 of 1-2 nM against both of the two isoforms.
  • HY-10520
    CGP 57380 Inhibitor 98.48%
    CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of Mnk1 with IC50 of 2.2 μM, but has no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.
  • HY-16982
    Cercosporamide Inhibitor
    Cercosporamide is a potent and selective Mnk inhibitor, and a orally bioavailable antifungal agent, suppresses phosphorylation of eIF4E and exhibits antileukemic effects.